Every coffee keeps the site running. Thank you!
Tech, gaming and the news that matters
Biopharmaceutical firms are extending messenger RNA technology beyond infectious disease vaccines to selectively reset immune system tolerances in chronic autoimmune disorders.
Targeted Immunomodulation
Phase II trial results indicate significant reductions in target inflammatory markers without compromising general host defense mechanisms, opening potential treatment pathways for millions of patients worldwide.
Next-generation sequencing costs dropping below key financial thresholds are enabling routine genomic profiling in clinical oncology workflows.
Pharmaceutical developers report significant reductions in early-stage candidate selection timelines through the integration of generative protein design models.
I know a lot of people are interested in selling their body parts and make money. You are…
Widespread adoption of metabolic therapies impacts medical device forecasts and encourages targeted clinical trials in cardiology.
Biopharmaceutical firms move mRNA-based personalized cancer vaccines into Phase II trials following positive preliminary data.
Healthcare networks are deploying machine learning models to forecast patient admission rates and optimize clinical staffing allocations.